Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
Heart failure (HF) in association with acute myocardial infarction is an emerging clinical problem. The benefits of aldosterone blockade have now been extended, with the selective aldosterone antagonist eplerenone demonstrating reduced mortality compared to placebo, in patients with post-myocardial infarction HF. The evidence supporting this agent will be briefly reviewed, followed by a discussion on the clinical implications of aldosterone antagonists in this clinical setting.
Ajani
Andrew E
AE
Department of Cardiology, Royal Melbourne Hospital, and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. andrew.ajani@mh.org.au
Marwick
Thomas H
TH
Krum
Henry
H
D002986:Clinical Trials as Topic; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone